Eli Lilly and Company NYQ · LLY
Price alert —
Sign in to get a one-time email the moment LLY crosses your price. Free accounts included.
Sign in / create a free accountEli Lilly and Company is a major pharmaceutical manufacturer that develops and sells prescription medications across the United States and international markets. The company's portfolio spans several therapeutic areas, with a particular focus on cardiometabolic health products, including various insulin formulations like Humalog, Basaglar, and Humulin that are widely used in diabetes treatment. As a large-cap healthcare stock in the drug manufacturing sector, Eli Lilly represents one of the industry's established players with global reach.
The stock is currently trading at $1,179.11, up 0.85% on the day. Over the past year, shares have moved within a range of $850.51 to $1,249.45, placing the current price closer to the upper end of that band. The stock sits in neutral technical territory, trading near its 21-day average with a distance of just 0.29 times its average true range. The RSI(2) reading of 77.1 suggests recent short-term buying momentum.
Looking ahead, investors may want to monitor how the stock behaves near its recent 52-week high and whether it can maintain its position in the upper portion of its yearly range. The company's next earnings report is scheduled for August 2026, which is well into the future. Broader pharmaceutical sector trends, regulatory developments, and any updates on the company's product pipeline could influence trading patterns in the coming weeks and months.
A plain-English snapshot built from the data on this page — not investment advice. Always do your own research.
above KC1 lower, +0.25 ATR from EMA21 — no notable pattern
- · Aligned with weak uptrend
Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.
Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.
Our cash-flow model pegs fair value near $524.39 (fair range $205–$524); today's price sits 132% above that estimate. The model's verdict is “Overvalued” and accounting quality screens as Weak. Model estimates only — do your own due diligence.
- ✓ Goodwill 5% of assets (organic growth)
- ✓ Positive retained earnings
- ✓ Gross margin 83% (pricing power)
- ✓ Net margin 35%
- ⚠ Debt exceeds cash
- ⚠ Quick ratio 0.65 (fragile)
- ⚠ Debt/equity 3.24 (fragile)
- ⚠ Receivables growing faster than revenue
Price implies ~40% growth (vs trailing rev yoy). Model estimate — do your own due diligence.
LLY is a $1.0 trillion company, priced at 42× last year's earnings, and it moves more calmly than the market (beta 0.5).
Options idea
See more →Earnings
See more →- Last reported
- 2026-04-30
- EPS (act / est)
- 8.55 / 6.79
- Surprise
- +25.9%
- Next report
- 2026-08-05
About
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25,…